Few medical screening debates have persisted as long or as contentiously as PSA testing for prostate cancer. A decade ago, the evidence suggested screening delivered essentially no survival benefit. New large trials and extended follow-up data have shifted that picture — modestly — while the harm side of the ledger remains sobering, a tension that every man over 50 and every clinician advising them must reckon with.
This updated Cochrane systematic review, searching literature through November 2025, synthesizes randomized controlled trial evidence comparing PSA-based prostate cancer screening against no screening. Building on the 2013 edition — which found no significant reduction in disease-specific or overall mortality — the update incorporates results from two substantial new trials plus longer follow-up from previously included studies. Using random-effects meta-analysis across RCTs, the review evaluated critical outcomes including prostate cancer-specific mortality, all-cause mortality, and adverse events, as well as diagnostic endpoints spanning localized, advanced, and metastatic disease staging. The inclusion of incidence rate ratios as the primary effect measure for dichotomous outcomes reflects a methodological rigor appropriate for trials with differing follow-up periods.
This update arrives at a pivotal moment. The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the PLCO trial — now with longer follow-up — have produced somewhat divergent signals, and how this Cochrane synthesis reconciles them will likely influence guidelines globally. Critically, PSA screening's central dilemma remains unchanged in structure even if the numbers have shifted: the test detects indolent, low-grade cancers that may never threaten life, driving overdiagnosis rates estimated in earlier reviews at 30–50%, leading to unnecessary biopsies, surgical complications, incontinence, and erectile dysfunction. Any incremental mortality benefit must be weighed against this substantial burden. The review's assessment of quality-of-life outcomes is therefore as consequential as its mortality findings. This is a potentially paradigm-influencing update for a question that directly affects hundreds of millions of aging men worldwide — making it one of the more consequential pieces of evidence synthesis in cancer screening this decade.